Surgery for malignant pleural mesothelioma

References

• Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J. Thorac. Oncol.1(2), 175–176 (2006).
   PubMed Web of Science ®Google Scholar
• Sarot IA. Extrapleural pulmonary resection and pleurectomy (pleuro-pneumonectomy) for tuberculosis and empyema. Trans. Annu. Meet. Natl Tuberc. Assoc.46, 253–254 (1950).
   Google Scholar
• Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax31(1), 15–24 (1976).
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Jaklitsch MT, Bueno R et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J. Thorac. Cardiovasc. Surg.128(1), 138–146 (2004).
   PubMed Web of Science ®Google Scholar
• Yan TD, Boyer M, Tin MM et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J. Thorac. Cardiovasc. Surg.138(3), 619–624 (2009).
   PubMed Web of Science ®Google Scholar
• Rusch VW, Rosenzweig K, Venkatraman E et al. A Phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg.122(4), 788–795 (2001).
   PubMed Web of Science ®Google Scholar
• Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol.18(7), 1196–1202 (2007).
   PubMed Web of Science ®Google Scholar
• de Perrot M, Feld R, Cho BC et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol.27(9), 1413–1418 (2009).
   PubMed Web of Science ®Google Scholar
• Krug LM, Pass HI, Rusch VW et al. Multicenter Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol.27(18), 3007–3013 (2009).
   PubMed Web of Science ®Google Scholar
• Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg.135(3), 620–626 (2008).
   PubMed Web of Science ®Google Scholar
• Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann. Thorac. Surg.85(2), 424–429 (2008).
   Google Scholar
• Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery125(3), 250–256 (1999).
   PubMed Web of Science ®Google Scholar
• Veillette G, Dominguez I, Ferrone C et al. Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experience. Arch. Surg.143(5), 476–481 (2008).
   PubMed Web of Science ®Google Scholar
• Virani S, Michaelson JS, Hutter MM et al. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J. Am. Coll. Surg.204(6), 1284–1292 (2007).
   PubMed Web of Science ®Google Scholar
• Ambrogi V, Mineo D, Gatti A, Pompeo E, Mineo TC. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J. Surg. Oncol.100(3), 199–204 (2009).
   PubMed Web of Science ®Google Scholar
• Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest103(4 Suppl.), 382S–384S (1993).
   Google Scholar
• Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin. Thorac. Cardiovasc. Surg.21(2), 132–148 (2009).
   PubMedGoogle Scholar
• Soysal O, Karaoglanoglu N, Demiracan S et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur. J. Cardiothorac. Surg.11(2), 210–213 (1997).
   PubMedGoogle Scholar
• Baldini EH, Recht A, Strauss GM et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg.63(2), 334–338 (1997).
   PubMed Web of Science ®Google Scholar
• Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin. Thorac. Cardiovasc. Surg.21(2), 149–153 (2009).
   PubMedGoogle Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg.117(1), 54–63 (1999).
   PubMed Web of Science ®Google Scholar
• Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg.68(5), 1799–1804 (1999).
   PubMed Web of Science ®Google Scholar
• Maggi G, Casadio C, Cianci R, Rena O, Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg.19(3), 346–350 (2001).
   PubMed Web of Science ®Google Scholar
• Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur. J. Cardiothorac. Surg.22(2), 298–305 (2002).
   PubMed Web of Science ®Google Scholar
• Flores RM, Krug LM, Rosenzweig KE et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J. Thorac. Oncol.1(4), 289–295 (2006).
   PubMed Web of Science ®Google Scholar
• Schipper PH, Nichols FC, Thomse KM et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann. Thorac. Surg.85(1), 257–264; discussion 64 (2008).
   PubMed Web of Science ®Google Scholar
• Pass HI, Temeck BK, Kranda K et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann. Surg. Oncol.4(8), 628–633 (1997).
   PubMed Web of Science ®Google Scholar
• Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg.115(2), 310–317; discussion 317–318 (1998).
   PubMedGoogle Scholar
• Moskal TL, Urschel JD, Anderson TM, Antkowiak JG, Takita H. Malignant pleural mesothelioma: a problematic review. Surg. Oncol.7(1–2), 5–12 (1998).
   Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21(14), 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD. Survival after conservative (palliative) management of pleural malignant mesothelioma. J. Surg. Oncol.78(3), 171–174 (2001).
   PubMed Web of Science ®Google Scholar
• Calavrezis A, Koschel G, Husselmann H et al. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981–1985. Klin. Wochenschr.66, 607–613 (1988).
   Google Scholar
• Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Nori D. Technique for external beam treatment for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.13(11), 1747–1752 (1987).
   PubMed Web of Science ®Google Scholar
• Yajnik S, Rosenzweig KE, Mychalczak B et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.56(5), 1319–1326 (2003).
   PubMed Web of Science ®Google Scholar
• Ahamad A, Stevens CW, Smythe WR et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.55(3), 768–775 (2003).
   PubMed Web of Science ®Google Scholar
• Forster KM, Smythe WR, Starkschall G et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int. J. Radiat. Oncol. Biol. Phys.55(3), 606–616 (2003).
   PubMed Web of Science ®Google Scholar
• Rice DC, Stevens CW, Correa AM et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann. Thorac. Surg.84(5), 1685–1692; discussion 1692–1693 (2007).
   PubMed Web of Science ®Google Scholar
• Allen AM, Czerminska M, Janne PA et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.65(3), 640–645 (2006).
   PubMed Web of Science ®Google Scholar
• Miles EF, Larrier NA, Kelsey CR et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int. J. Radiat. Oncol. Biol. Phys.71(4), 1143–1150 (2008).
   PubMed Web of Science ®Google Scholar
• Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.21(2), 159–163 (2009).
   Google Scholar
• Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.21(2), 177–187 (2009).
   Google Scholar
• Friedberg JS, Mick R, Stevenson J et al. A Phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann. Thorac. Surg.75(3), 952–959 (2003).
   Google Scholar
• Friedberg JS, Mick R, Stevenson JP et al. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J. Clin. Oncol.22(11), 2192–2201 (2004).
   PubMed Web of Science ®Google Scholar
• Tilleman TR, Richards WG, Zellos L et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a Phase II prospective study. J. Thorac. Cardiovasc. Surg.138(2), 405–411 (2009).
   PubMed Web of Science ®Google Scholar
• Richards WG, Zellos L, Bueno R et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J. Clin. Oncol.24(10), 1561–1567 (2006).
   PubMed Web of Science ®Google Scholar
• Zellos L, Richards WG, Capalbo L et al. A Phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg.137(2), 453–458 (2009).
   Google Scholar
• Jackman D. Current options for systemic therapy in mesothelioma. Semin. Thorac. Cardiovasc. Surg.21, 154–158 (2009).
   Google Scholar
• Hartman M, Esposito J, Yeap B, Sugarbaker D. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J. Thorac. Cardiovasc. Surg.139(5), 1233–1240 (2010).
   Google Scholar
• Vogelzang NJ. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer50(Suppl. 1), S23–S24 (2005).
   Google Scholar
• Castagneto B, Zai S, Dongiovanni D et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a Phase II study. Am. J. Clin. Oncol.28(3), 223–226 (2005).
   PubMed Web of Science ®Google Scholar
• Kalmadi SR, Rankin C, Kraut MJ et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a Phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer60(2), 259–263 (2008).
   PubMed Web of Science ®Google Scholar
• van Haarst JM, Baas P, Manegold C et al. Multicentre Phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br. J. Cancer86(3), 342–345 (2002).
   PubMed Web of Science ®Google Scholar
• Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer64(3), 308–313 (2009).
   PubMedGoogle Scholar
• Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br. J. Cancer99(1), 44–50 (2008).
   PubMed Web of Science ®Google Scholar
• Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol.22(17), 3451–3457 (2004).
   PubMed Web of Science ®Google Scholar
• Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.9(4), 347–355 (1997).
   Google Scholar
• Corson JM. Pathology of mesothelioma. Thorac. Surg. Clin.14(4), 447–460 (2004).
   PubMedGoogle Scholar
• Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am. J. Pathol.108(1), 80–88 (1982).
   PubMed Web of Science ®Google Scholar
• Travis WD, Colby TV, Corrin B, Brambilla E. World Health Organization International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours (3rd Edition). Travis WD (Ed.). Springer, Berlin, Germany (1999).
   Google Scholar
• Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest108(4), 1122–1128 (1995).
   PubMed Web of Science ®Google Scholar
• Richards WG, Godleski JJ, Yeap BY et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer116(6), 1510–1517 (2010).
   Google Scholar
• Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.21(2), 97–104 (2009).
   PubMedGoogle Scholar
• Gill R, Gerbaudo V, Sugarbaker D, Hatabu H. Current trends in radiologic management of malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.21, 111–120 (2009).
   PubMedGoogle Scholar
• Mujoomdar A, Matsuoka S, Hatabu H et al. Reduced lung volume measured by CT predicts unresectability in mesothelioma patients. Presented at: 9th Biennial Conference of the International Mesothelioma Interest Group, 2008. Amsterdam, The Netherlands, 24–26 September 2008.
   Google Scholar
• Gordon GJ, Dong L, Yeap BY et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J. Natl Cancer Inst.101(9), 678–686 (2009).
   PubMed Web of Science ®Google Scholar
• Bueno R. Making the case for molecular staging of malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.21(2), 188–193 (2009).
   Google Scholar
• Mujoomdar A, Tilleman T, Richards W, Bueno R, Sugarbaker D. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J. Thorac. Cardiovasc. Surg. (2009) (In Press).
   Google Scholar
• Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer44(1), 46–53 (2008).
   PubMed Web of Science ®Google Scholar
• Figure 103.2. In: Adult Chest Surgery (First Edition). The McGraw-Hill Companies, NY, USA (2009).
   Google Scholar
• Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin. Thorac Cardiovasc. Surg.21(2), 132–148 (2009).
   PubMedGoogle Scholar